Journal
FRONTIERS IN CARDIOVASCULAR MEDICINE
Volume 8, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcvm.2021.742178
Keywords
obesity; inflammation; lipotoxicity; HFpEF; cardiometabolic disease
Categories
Funding
- Swiss National Science Foundation [310030_197557]
- Swiss Heart Foundation [FF20094, FF19056, FF19045]
- Stiftung fur wissenschaftliche Forschung
- Olga Mayenfisch Foundation
- Swiss Life Foundation
- Kurt und Senta-Hermann Stiftung
- EMDO Stiftung
- Schweizerische Diabetes-Stiftung
- Holcim Foundation
- Forschungskredit Candoc grant from the University of Zurich
- Foundation of Cardiovascular Research - Zurich Heart House
- Theodor und Ida Herzog-Egli-Stiftung
- Swiss National Science Foundation (SNF) [310030_197557] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Inflammatory processes play a crucial role in the development of metabolic cardiomyopathy, affecting cardiovascular health by influencing the function and structure of cardiac cells, exacerbating cardiovascular disease.
Overlapping pandemics of lifestyle-related diseases pose a substantial threat to cardiovascular health. Apart from coronary artery disease, metabolic disturbances linked to obesity, insulin resistance and diabetes directly compromise myocardial structure and function through independent and shared mechanisms heavily involving inflammatory signals. Accumulating evidence indicates that metabolic dysregulation causes systemic inflammation, which in turn aggravates cardiovascular disease. Indeed, elevated systemic levels of pro-inflammatory cytokines and metabolic substrates induce an inflammatory state in different cardiac cells and lead to subcellular alterations thereby promoting maladaptive myocardial remodeling. At the cellular level, inflammation-induced oxidative stress, mitochondrial dysfunction, impaired calcium handling, and lipotoxicity contribute to cardiomyocyte hypertrophy and dysfunction, extracellular matrix accumulation and microvascular disease. In cardiometabolic patients, myocardial inflammation is maintained by innate immune cell activation mediated by pattern recognition receptors such as Toll-like receptor 4 (TLR4) and downstream activation of the NLRP3 inflammasome and NF-kappa B-dependent pathways. Chronic low-grade inflammation progressively alters metabolic processes in the heart, leading to a metabolic cardiomyopathy (MC) phenotype and eventually to heart failure with preserved ejection fraction (HFpEF). In accordance with preclinical data, observational studies consistently showed increased inflammatory markers and cardiometabolic features in patients with HFpEF. Future treatment approaches of MC may target inflammatory mediators as they are closely intertwined with cardiac nutrient metabolism. Here, we review current evidence on inflammatory processes involved in the development of MC and provide an overview of nutrient and cytokine-driven pro-inflammatory effects stratified by cell type.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available